Form 4: Akari Therapeutics CFO Receives Stock Grant
Insider Transaction (Form 4)
Kameel D. Farag, Interim CFO of Akari Therapeutics Plc, received 1,130 shares of common stock on July 16, 2026.
Summary
- Grant/award: acquired 1,130 American Depositary Shares representing Ordinary Shares at $11.50 ($12,995) on July 16, 2026; holds 21,581 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kameel D. Farag — Officer (Interim CFO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-16 | Grant/award | American Depositary Shares representing Ordinary Shares | 1,130 | $12 | $13.0K | 21,581 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-16 | Grant/award (1,130 shares) |
Keywords
insider transaction, Form 4, AKTX, Akari Therapeutics Plc, neutral, Kameel D. Farag
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.